...Hello, everyone. I am Sunao Manabe, Executive Chairperson and CEO of Daiichi Sankyo. Thank you for joining Daiichi Sankyo's Oncology Business Briefing. Please go to slide 3. Here is today's agenda. After my part, Ken Keller will provide us with an overview of our Global Oncology business, then Dan and Markus will tell us about US and European Oncology Business performance, how we are establishing Daiichi Sankyo's position in Oncology and launch readiness for upcoming key events. After that, Ken will close the presentation, and we will open the floor for questions from the audience. Next slide, please. Before moving to the next agenda item, let me briefly introduce our speakers. Next slide, please. Ken Keller, our Global Head of the Oncology business, joined Daiichi Sankyo in 2014. He revamped our US business structure to focus on multiple oncology launches, including ENHERTU to achieve Daiichi Sankyo's 2025 goal and 2030 vision. Next, please. Dan Switzer, our Head of the US Oncology Business...